Adverum Biotechnologies, Inc. (ADVM): Price and Financial Metrics

Adverum Biotechnologies, Inc. (ADVM): $14.16

0.50 (-3.41%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add ADVM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#99 of 363

in industry

ADVM Price/Volume Stats

Current price $14.16 52-week high $29.70
Prev. close $14.66 52-week low $6.81
Day low $13.93 Volume 67,437
Day high $14.82 Avg. volume 251,402
50-day MA $16.67 Dividend yield N/A
200-day MA $14.15 Market Cap 293.89M

ADVM Stock Price Chart Interactive Chart >

ADVM POWR Grades

  • Sentiment is the dimension where ADVM ranks best; there it ranks ahead of 75.96% of US stocks.
  • ADVM's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
  • ADVM's current lowest rank is in the Momentum metric (where it is better than 18.05% of US stocks).

ADVM Stock Summary

  • ADVERUM BIOTECHNOLOGIES INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 10.97% of US listed stocks.
  • ADVM's price/sales ratio is 23.57; that's higher than the P/S ratio of 94.84% of US stocks.
  • With a year-over-year growth in debt of -30.98%, ADVERUM BIOTECHNOLOGIES INC's debt growth rate surpasses merely 10.5% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to ADVERUM BIOTECHNOLOGIES INC, a group of peers worth examining would be FULC, DCPH, SABS, MTNB, and ABEO.
  • Visit ADVM's SEC page to see the company's official filings. To visit the company's web site, go to www.adverum.com.

ADVM Valuation Summary

  • ADVM's EV/EBIT ratio is -0.3; this is 102.05% lower than that of the median Healthcare stock.
  • ADVM's price/sales ratio has moved down 2961 over the prior 115 months.

Below are key valuation metrics over time for ADVM.

Stock Date P/S P/B P/E EV/EBIT
ADVM 2023-12-29 21.1 0.7 -0.6 -0.3
ADVM 2023-12-28 21.2 0.7 -0.6 -0.3
ADVM 2023-12-27 21.1 0.7 -0.6 -0.3
ADVM 2023-12-26 22.4 0.8 -0.6 -0.3
ADVM 2023-12-22 22.2 0.8 -0.6 -0.3
ADVM 2023-12-21 21.6 0.8 -0.6 -0.3

ADVM Growth Metrics

    Its 2 year cash and equivalents growth rate is now at -29.74%.
  • Its year over year price growth rate is now at -75.37%.
  • The 2 year price growth rate now stands at -95.53%.
ADVM's revenue has moved down $2,003,000 over the prior 49 months.

The table below shows ADVM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0 -115.431 -156.209
2022-06-30 0 -109.419 -154.44
2022-03-31 0 -114.455 -155.012
2021-12-31 7.5 -107.831 -145.54
2021-09-30 7.5 -104.24 -148.763
2021-06-30 7.5 -104.988 -138.17

ADVM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ADVM has a Quality Grade of C, ranking ahead of 36.31% of graded US stocks.
  • ADVM's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
  • REGN, PRGO, and ORMP are the stocks whose asset turnover ratios are most correlated with ADVM.

The table below shows ADVM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.015 1 -0.294
2021-03-31 0.017 1 -0.306
2020-12-31 0.000 NA -0.331
2020-09-30 0.000 NA -0.345
2020-06-30 0.001 1 -0.416
2020-03-31 0.001 1 -0.447

ADVM Price Target

For more insight on analysts targets of ADVM, see our ADVM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $3.57 Average Broker Recommendation 1.94 (Hold)

Adverum Biotechnologies, Inc. (ADVM) Company Bio


Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company was founded in 2006 and is based in Menlo Park, California.


ADVM Latest News Stream


Event/Time News Detail
Loading, please wait...

ADVM Latest Social Stream


Loading social stream, please wait...

View Full ADVM Social Stream

Latest ADVM News From Around the Web

Below are the latest news stories about ADVERUM BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate ADVM as an investment opportunity.

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be presented at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024. “We are very pleased to have the opportunity to present our initial Phase 2 efficacy and saf

Yahoo | December 7, 2023

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and Star Seyedkazemi, chief development officer of Adverum Biotechnologies, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Wednesday, November 29, 2023 at 3:50 p.m.

Yahoo | November 28, 2023

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels observed in the OPTIC trial - - Reported OPTIC long-term follow-up data demonstrating that patients continue to experience substantial, long-term benefit from Ixo-vec through 3 years of follow-up - - Initial Phase 2 LUNA efficacy and safety data anticipated in Q4 2023 - - Cash runway projected into 2

Yahoo | November 9, 2023

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors

REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023. Dr. Nicholson brings over forty years of pharmaceutical experience, a proven track record in drug development, and deep experience

Yahoo | November 6, 2023

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden - - 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose entirely free of injections at year 3 - - Durable aflibercept protein levels up to 4.5 years after a single Ixo-vec IVT injection - - Ixo-vec continues to be generally wel

Yahoo | November 4, 2023

Read More 'ADVM' Stories Here

ADVM Price Returns

1-mo -29.20%
3-mo 88.10%
6-mo -5.60%
1-year 88.67%
3-year -84.98%
5-year -72.98%
YTD 88.10%
2023 29.91%
2022 -67.07%
2021 -83.76%
2020 -5.90%
2019 265.71%

Continue Researching ADVM

Here are a few links from around the web to help you further your research on Adverum Biotechnologies Inc's stock as an investment opportunity:

Adverum Biotechnologies Inc (ADVM) Stock Price | Nasdaq
Adverum Biotechnologies Inc (ADVM) Stock Quote, History and News - Yahoo Finance
Adverum Biotechnologies Inc (ADVM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!